Biologics

News Biologics

• Spinnovation launch new biologics division with unique service provision

  Frederic Girard, CEO Spinnovation Analytical BV announced the launch of a new division of the company – Spinnovation Biologics – at the annual meeting of the Flanders Biotech group. Extending the company’s current contract research and contract analysis services, the new division will provide a uniq more

• Chris Beaver joins Pharmanet as Director, Immunochemistry Services

  PharmaNet Development Group, Inc. announced that Chris Beaver, PhD has joined the Company as Director, Immunochemistry Services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including assay more

• Ablynx eligible for milestone payment as Pfizer initiates Phase I clinical trial with second Anti-TNF-alpha Nanobody

  Ablynx announced that it is now eligible for a milestone payment of $3 million as a result of the initiation by Pfizer of a new Phase I clinical study in healthy volunteers for a second Nanobody (PF-05230905) targeting tumour necrosis factor alpha (TNF-alpha). Pfizer's lead anti-TNF-alpha Nanobody more

White papers Biologics

• Alliances in Drug Discovery - The Chemical Element
  

  Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand deals amounting to a cumulative payout of US$ 17bn have been signed by pharmaceutical and biotech players in a span of two decades. In the past five years the industry's mania to develop new generation blockbuster drugs has taken on a new sense of urgency as 64% of the alliance value was inked and paid out during the period. more

Publications Biologics

• Pharmaceuticals, Vol. 6, Pages 579-603: Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production

  From 2006 to 2011, an average of 15 novel recombinant protein therapeutics have been approved by US Food and Drug Administration (FDA) annually. In addition, the expiration of blockbuster biologics has also spurred the emergence of biosimilars. The increasing numbers of innovator biologic products a more

• Drug Design and Discovery: Translational Biomedical Science Varies Among Countries

  Abstract Drug design and discovery is an innovation process that translates the outcomes of fundamental biomedical research into therapeutics that are ultimately made available to people with medical disorders in many countries throughout the world. To identify which nations succeed, exceed, or more

• Pharmaceuticals, Vol. 6, Pages 557-578: Biologics in Dermatology

  Skin and subcutaneous diseases affect millions of people worldwide, causing significant morbidity. Biologics are becoming increasingly useful for the treatment of many skin diseases, particularly as alternatives for patients who have failed to tolerate or respond to conventional systemic therapies. more

Market studies Biologics

• Algeria Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: With the push into emerging markets by pharmaceutical companies and the dangers of importing drugs into the Algerian market well documented, it makes sense that large multinational drugmakers would want to partner with local companies. High rates of foreign direct investment in the past ye more

• Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

  GBI Research, a leading business intelligence provider, has released its latest research “Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth” which examines two major trends already impacting on marketing strategies in the global pharmaceutical environm more

• Global Orthopedic Devices Market 2011-2015

  TechNavio's analysts forecast the Global Orthopedic Devices market to grow at a CAGR of 6.6 percent over the period 2011-2015. One of the key factors contributing to this market growth is rising rates of co-morbidities due to lifestyle changes. The Global Orthopedic Devices market has also been witn more

Websites Biologics